Study finds, Pharmacogenomic Effects on Risperidone Outcomes
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The findings of the study suggested that risperidone AEs may be more common in children and adolescents who are CYP2D6 PMs/IMs (poor/intermediate metabolizers).

A research was conducted to determine the association between genetic variants reported to affect risperidone and adverse events (AEs) in children and adolescents.

Individuals aged 18 and under who had been exposed to risperidone for more than 4 weeks were included in a deidentified DNA biobank. The main result was the frequency of AE as a function of genotype. Individuals were divided into three groups: metabolizers for CYP2D6, CYP3A4, and CYP3A5; wild type, heterozygote, or homozygote for various single nucleotide variants for DRD2, DRD3, HTR2A, and HTR2C; and wild type versus nonwild type for several uncommon variants in ABCG2, ABCB1, and HTR2C. A Fisher exact test and logistic regression were used to test each classification's association with AEs, and statistically relevant classifications were used in a final logistic regression.

Results:
--The final cohort included 257 individuals. AEs were more common in CYP2D6 poor/intermediate metabolizers (PMs/IMs) than normal/rapid/ultrarapid metabolizers (NMs/RMs/UMs) in univariate and multivariate analysis.

--HTR2A-rs6311 heterozygotes and homozygotes had fewer AEs than wild types in logistic regression but not in univariate analysis.

--In the final multivariable model adjusting for age, race, sex, and risperidone dose, AEs were associated with CYP2D6 and HTR2A-rs6311 both consistent with previous studies.

In conclusion, risperidone AEs may be more common in children and adolescents who are CYP2D6 PMs/IMs. Only CYP2D6 has a stable correlation and enough evidence for clinical use among the genes and variants tested.

Source: https://journals.lww.com/jrnldbp/Abstract/2021/04000/Evidence_for_Pharmacogenomic_Effects_on.5.aspx
Like
Comment
Share